Previous 10 | Next 10 |
ArcelorMittal S.A. (NYSE:MT) is scheduled to announce Q1 earnings results on Thursday, May 5th, before market open. The consensus EPS Estimate is $3.41 (+76.7% Y/Y) and the consensus Revenue Estimate is $20.83B (+28.7% Y/Y). Over the last 1 year, MT has beaten EPS estimates 75% of the time an...
Gainers: Sharps Technology (STSS) +43%. TransMedics Group (TMDX) +30%. Super Micro Computer (SMCI) +25%. CarParts.com (PRTS) +25%. Superior Industries International (SUP) +22%. Livent (LTHM) +23%. Bright Health Group (BHG) +21%. eHealth (EHTH) +19%. BlueLinx Holdings (BXC) +18%. Kimball Inter...
Gainers: Bright Health Group BHG +21%. TransMedics Group TMDX +21%. Belite Bio (BLTE) +11%. Sharps Technology STSS +11%. Immutep (IMMP) +7%. Losers: Connect Biopharma CNTB -45%. Amarin AMRN -43%. Kezar Life Sciences (KZR) -35%. MacroGenic...
TransMedics (NASDAQ:TMDX) continues to trade higher in the morning hours Wednesday after the commercial-stage med-tech company raised its full-year guidance following a strong revenue beat for 1Q 2022. In reaction, Cowen analyst Joshua Jennings raised his price target on the stock to $35...
Transmedics Group, Inc. (TMDX) Q1 2022 Earnings Conference Call May 03, 2022 05:00 PM ET Company Participants Brian Johnston - Gilmartin Group Waleed Hassanein - President and CEO Stephen Gordon - CFO Conference Call Participants Bill Plovanic - Canaccord Genuity Cecilia Furlong - Morgan Stan...
Shares of TransMedics Group (NASDAQ:TMDX) have jumped 16.9% to $25.56 in Tuesday aftermarket trading, after the medical technology company raised its FY 2022 guidance. TMDX, in its Q1 2022 earnings report, said that it now expects FY 2022 net revenue to be in the range of $59M-$65M vs. previo...
TransMedics Group press release (NASDAQ:TMDX): Q1 GAAP EPS of -$0.38 misses by $0.01. Revenue of $15.9M (+123.9% Y/Y) beats by $6.25M. Updating FY 2022 net revenue to be in the range of $59 million to $65 million. Cash, cash equivalents and marketable securities were $72.0 million as of March...
TransMedics Reports First Quarter 2022 Financial Results PR Newswire ANDOVER, Mass. , May 3, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patien...
TransMedics Group (NASDAQ:TMDX) is scheduled to announce Q1 earnings results on Tuesday, May 3rd, after market close. The consensus EPS Estimate is -$0.39 and the consensus Revenue Estimate is $9.65M (+35.9% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downwar...
ABNB, ACHC, ADC, AHT, AIG, AIZ, AKAM, ALR, AMCR, AMD, ANDE, APPH, AQST, ATEN, AYX, BFAM, BGFV, BLKB, BNFT, BNL, BTG, BXC, CGBD, CHCT, CNDT, CNR, COKE, CRK, CRUS, CTSO, CWH, CZR, DENN, DHC, DMTK, EGY, EHTH, EIX, ENLC, ENVA, EQX, EXR, FLGT, FPI, FRSH, GLAD, GLRE, GNW, GPOR, GRBK, HASI, HLF, HRZ...
News, Short Squeeze, Breakout and More Instantly...
TransMedics Group Inc. Company Name:
TMDX Stock Symbol:
NYSE Market:
TransMedics Group Inc. Website:
TransMedics to Report Second Quarter 2024 Financial Results on July 31, 2024 PR Newswire ANDOVER, Mass. , July 17, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant...
2024-07-04 23:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Shares of TransMedics Group, Inc. (NASDAQ: TMDX) traded at a new 52-week high today and are currently trading at $139.5. So far today, approximately 249.23k shares have been exchanged, as compared to an average 30-day volume of 655.52k shares. TransMedics Group, Inc., a commercial-stage medic...